CD8A and neoplasm: DLBCLs with EZH2 mutations manifest silencing of MHC I and MHC II and reduced CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs), hence introducing EZH2i in the standard of care therapeutic regimen for DLBCL may be beneficial [174].